NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 96 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $50,772 | -20.1% | 19,603 | +25.9% | 0.00% | – |
| Q1 2023 | $63,550 | -18.7% | 15,576 | 0.0% | 0.00% | – |
| Q4 2022 | $78,192 | -61.6% | 15,576 | 0.0% | 0.00% | – |
| Q3 2022 | $203,734 | +9.5% | 15,576 | +7.4% | 0.00% | – |
| Q2 2022 | $186,000 | -2.1% | 14,498 | +16.3% | 0.00% | – |
| Q1 2022 | $190,000 | -14.0% | 12,466 | 0.0% | 0.00% | – |
| Q4 2021 | $221,000 | -14.3% | 12,466 | +1.7% | 0.00% | -100.0% |
| Q3 2021 | $258,000 | +6.6% | 12,259 | 0.0% | 0.00% | – |
| Q2 2021 | $242,000 | -23.9% | 12,259 | +12.2% | 0.00% | -100.0% |
| Q1 2021 | $318,000 | +0.3% | 10,925 | +4.5% | 0.00% | 0.0% |
| Q4 2020 | $317,000 | +105.8% | 10,458 | -16.5% | 0.00% | – |
| Q1 2020 | $154,000 | -28.4% | 12,524 | +7.6% | 0.00% | – |
| Q4 2019 | $215,000 | – | 11,642 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |